Implantable glucose sensor
    1.
    发明授权
    Implantable glucose sensor 失效
    植入式葡萄糖传感器

    公开(公告)号:US5165407A

    公开(公告)日:1992-11-24

    申请号:US682560

    申请日:1991-04-09

    摘要: Implantable enzymatic sensors (25, 43, 44) for biochemicals such as glucose are provided having an ideal size and geometry for optional long term implantation and linear responses over the concentration ranges of interest. The sensors (25, 43, 44) include an elongated body (10, 26, 46) supporting an indicating electrode section having an appropriate enzyme immobilized thereon to present an enzymatic indicating surface (21, 33, 54). A permeable synthetic polymer membrane (24, 42, 56) is applied over the sensor body (10, 26, 46) to protect the enzyme and regulate diffusion of analyte therethrough, to ensure linearity of sensor response. The sensors (25, 43) are of flexible design and can be implanted using a catheter. Alternately, the sensor (44) includes an internal indicating electrode body (46) housed within an apertured, hollow needle (48). A holder (66) affixed to the needle (48) allows for easy manipulation and implantation of the sensor (44).

    摘要翻译: 提供了用于生物化学品如葡萄糖的可植入酶传感器(25,43,44),其具有理想的尺寸和几何尺寸,用于在所关注的浓度范围内进行可选的长期植入和线性响应。 传感器(25,43,44)包括支撑指示电极部分的细长体(10,26,46),所述指示电极部分具有固定在其上的合适的酶以呈现酶指示表面(21,33,54)。 将可渗透的合成聚合物膜(24,42,56)施加在传感器主体(10,26,46)上以保护酶并调节分析物通过其的扩散,以确保传感器响应的线性。 传感器(25,43)具有柔性设计,并且可以使用导管植入。 或者,传感器(44)包括容纳在有孔的空心针(48)内的内部指示电极体(46)。 固定在针(48)上的支架(66)可以方便地操作和植入传感器(44)。

    PHARMACEUTICAL COMPOSITIONS COMPRISING N-(4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4-ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE
    8.
    发明申请
    PHARMACEUTICAL COMPOSITIONS COMPRISING N-(4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4-ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE 有权
    包含N-(4-(2-氨基-3-氯代吡咯-4-基)-3-氟乙烯基)-4-乙氧基-1-(4-氟苯基)-2-氧代-1,2-二氢吡啶-3-酮的药物组合物 -CARBOXAMIDE

    公开(公告)号:US20150065719A1

    公开(公告)日:2015-03-05

    申请号:US14486139

    申请日:2014-09-15

    IPC分类号: C07D401/12

    CPC分类号: C07D401/12 C07D213/82

    摘要: Disclosed are salts and crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof. Also disclosed are at least one pharmaceutical composition comprising at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, at least one method of using at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide to treat cancer and/or other proliferative diseases, and processes to prepare crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof.

    摘要翻译: 公开了N-(4-(2-氨基-3-氯吡啶-4-基氧基)-3-氟苯基)-4-乙氧基-1-(4-氟苯基)-2-氧代-1,2 - 二氢吡啶-3-甲酰胺及其盐。 还公开了至少一种药物组合物,其包含至少一种结晶形式的N-(4-(2-氨基-3-氯吡啶-4-基氧基)-3-氟苯基)-4-乙氧基-1-(4-氟苯基) -2-氧代-1,2-二氢吡啶-3-甲酰胺,至少一种使用至少一种结晶形式的N-(4-(2-氨基-3-氯吡啶-4-基氧基)-3-氟苯基) -4-乙氧基-1-(4-氟苯基)-2-氧代-1,2-二氢吡啶-3-甲酰胺,以治疗癌症和/或其他增殖性疾病,以及制备N-(4-(2 -3-氨基-3-氯吡啶-4-基氧基)-3-氟苯基)-4-乙氧基-1-(4-氟苯基)-2-氧代-1,2-二氢吡啶-3-甲酰胺及其盐。

    Pharmaceutical compositions comprising N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-OXO-1,2-dihydropyridine-3-carboxamide
    9.
    发明授权
    Pharmaceutical compositions comprising N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-OXO-1,2-dihydropyridine-3-carboxamide 有权
    包含N-(4-(2-氨基-3-氯吡啶-4-基氧基)-3-氟苯基)-4-乙氧基-1-(4-氟苯基)-2-氧代-1,2-二氢吡啶-3 甲酰胺

    公开(公告)号:US08911785B2

    公开(公告)日:2014-12-16

    申请号:US13643561

    申请日:2011-04-29

    CPC分类号: C07D401/12 C07D213/82

    摘要: Disclosed are salts and crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof. Also disclosed are at least one pharmaceutical composition comprising at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, at least one method of using at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide to treat cancer and/or other proliferative diseases, and processes to prepare crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof.

    摘要翻译: 公开了N-(4-(2-氨基-3-氯吡啶-4-基氧基)-3-氟苯基)-4-乙氧基-1-(4-氟苯基)-2-氧代-1,2 - 二氢吡啶-3-甲酰胺及其盐。 还公开了至少一种药物组合物,其包含至少一种结晶形式的N-(4-(2-氨基-3-氯吡啶-4-基氧基)-3-氟苯基)-4-乙氧基-1-(4-氟苯基) -2-氧代-1,2-二氢吡啶-3-甲酰胺,至少一种使用至少一种结晶形式的N-(4-(2-氨基-3-氯吡啶-4-基氧基)-3-氟苯基) -4-乙氧基-1-(4-氟苯基)-2-氧代-1,2-二氢吡啶-3-甲酰胺,以治疗癌症和/或其他增殖性疾病,以及制备N-(4-(2 -3-氨基-3-氯吡啶-4-基氧基)-3-氟苯基)-4-乙氧基-1-(4-氟苯基)-2-氧代-1,2-二氢吡啶-3-甲酰胺及其盐。